- Home
- REGN vs BDX Comparison
REGN vs BDX Comparison
Compare REGN & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- BDX
- Stock Information
- Founded
- REGN 1988
- BDX 1897
- Country
- REGN United States
- BDX United States
- Employees
- REGN N/A
- BDX N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- BDX Medical/Dental Instruments
- Sector
- REGN Health Care
- BDX Health Care
- Exchange
- REGN Nasdaq
- BDX Nasdaq
- Market Cap
- REGN 63.4B
- BDX 58.9B
- IPO Year
- REGN 1991
- BDX 1962
- Fundamental
- Price
- REGN $490.28
- BDX $172.57
- Analyst Decision
- REGN Buy
- BDX Buy
- Analyst Count
- REGN 23
- BDX 9
- Target Price
- REGN $891.17
- BDX $235.63
- AVG Volume (30 Days)
- REGN 1.5M
- BDX 3.6M
- Earning Date
- REGN 04-29-2025
- BDX 05-01-2025
- Dividend Yield
- REGN 0.36%
- BDX 2.41%
- EPS Growth
- REGN 16.49
- BDX 14.07
- EPS
- REGN 39.43
- BDX 5.16
- Revenue
- REGN $14,085,700,000.00
- BDX $20,867,000,000.00
- Revenue This Year
- REGN N/A
- BDX $9.28
- Revenue Next Year
- REGN $6.97
- BDX $4.92
- P/E Ratio
- REGN $12.43
- BDX $33.43
- Revenue Growth
- REGN 7.52
- BDX 5.84
- 52 Week Low
- REGN $485.00
- BDX $163.33
- 52 Week High
- REGN $1,211.20
- BDX $251.99
- Technical
- Relative Strength Index (RSI)
- REGN 32.32
- BDX 38.31
- Support Level
- REGN $590.15
- BDX $169.60
- Resistance Level
- REGN $608.17
- BDX $176.43
- Average True Range (ATR)
- REGN 18.79
- BDX 3.46
- MACD
- REGN -3.82
- BDX 1.54
- Stochastic Oscillator
- REGN 3.98
- BDX 40.36
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About BDX Becton Dickinson and Company
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.